Ixekizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bullous Pemphigoid
Conditions
Bullous Pemphigoid, Pemphigoid
Trial Timeline
Aug 15, 2017 → Jun 6, 2019
NCT ID
NCT03099538About Ixekizumab
Ixekizumab is a phase 2 stage product being developed by Eli Lilly for Bullous Pemphigoid. The current trial status is completed. This product is registered under clinical trial identifier NCT03099538. Target conditions include Bullous Pemphigoid, Pemphigoid.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05855967 | Approved | Completed |
| NCT04259346 | Phase 1 | Completed |
| NCT03942042 | Approved | Completed |
| NCT03848416 | Phase 1 | Completed |
| NCT03848403 | Phase 1 | Terminated |
| NCT03485976 | Phase 2 | Completed |
| NCT03099538 | Phase 2 | Completed |
| NCT03137160 | Phase 2 | Completed |
| NCT03073213 | Phase 1 | Completed |
| NCT02387801 | Phase 3 | Completed |
Competing Products
8 competing products in Bullous Pemphigoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| QGE031 + Placebo | Novartis | Phase 2 | 52 |
| Azathioprine or Mycophenolate mofetil | Roche | Phase 2 | 52 |
| dupilumab + Matching Placebo + Oral corticosteroids (OCS) | Sanofi | Phase 2/3 | 64 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| BIV009 | Sanofi | Phase 1 | 32 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 3 | 74 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 2/3 | 62 |